| Withdrawn | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosu NCT06752876 | Caribou Biosciences, Inc. | Phase 1 |
| Not Yet Recruiting | The Relation Between Serum Zinc and Lupus Nephritis NCT06564181 | Assiut University | — |
| Not Yet Recruiting | Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis NCT07493655 | Federal University of Maranhao | N/A |
| Not Yet Recruiting | CHT105 for the Treatment of Refractory Lupus Nephritis NCT07517536 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Not Yet Recruiting | Anti-alpha-actinin Antibodies and Lupus Nephritis Activity NCT07505576 | Assiut University | — |
| Not Yet Recruiting | A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis NCT07393451 | Simcere Pharmaceutical Co., Ltd | Phase 2 |
| Recruiting | SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus NCT07523542 | Beijing Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus NCT07364396 | Curocell Inc. | Phase 1 / Phase 2 |
| Withdrawn | A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis NCT04883619 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis NCT07109986 | Nanjing IASO Biotechnology Co., Ltd. | Phase 1 |
| Completed | Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Co NCT07031674 | Yipeng Liu | — |
| Recruiting | LUPKYNIS Drug-use Results Survey NCT07053891 | Otsuka Pharmaceutical Co., Ltd. | — |
| Not Yet Recruiting | Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis NCT07053800 | Autolus Limited | Phase 2 |
| Recruiting | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE NCT07015983 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 2 |
| Enrolling By Invitation | A Study of KITE-363 in Participants With Refractory Autoimmune Diseases NCT07038447 | Kite, A Gilead Company | Phase 1 |
| Recruiting | Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Pa NCT06711887 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children NCT06904729 | Guangzhou Women and Children's Medical Center | Phase 3 |
| Active Not Recruiting | A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With S NCT06544330 | Synthekine | Phase 1 |
| Withdrawn | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythem NCT06429800 | Atara Biotherapeutics | Phase 1 |
| Recruiting | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease NCT06925542 | CRISPR Therapeutics | Phase 1 |
| Recruiting | Phase IIa Study for IPG11406 in Patients With Lupus Nephritis NCT06717815 | Nanjing Immunophage Biotech Co., Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases NCT06255028 | Century Therapeutics, Inc. | Phase 1 |
| Recruiting | CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis NCT06785519 | He Huang | EARLY_Phase 1 |
| Not Yet Recruiting | US Zamto-cel Autoimmune Diseases NCT06708845 | Miltenyi Biomedicine GmbH | Phase 1 |
| Not Yet Recruiting | Association Between Neuropathy and Some Autoantibodies in Systemic Lupus Erythematosus (SLE) Patients NCT06610422 | Assiut University | — |
| Recruiting | Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus NCT06796569 | Sohag University | — |
| Not Yet Recruiting | Universal CAR-T Cell Therapy for Refractory Lupus Nephritis NCT06681337 | Bioray Laboratories | EARLY_Phase 1 |
| Enrolling By Invitation | A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease NCT06375993 | Adicet Therapeutics | Phase 1 |
| Recruiting | Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN NCT06527872 | GlaxoSmithKline | — |
| Recruiting | Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients NCT06631404 | Sohag University | — |
| Recruiting | Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus NCT07225387 | NephroNet, Inc. | Phase 4 |
| Not Yet Recruiting | Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus Nephritis NCT06485648 | Chinese PLA General Hospital | EARLY_Phase 1 |
| Recruiting | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis NCT06581198 | Novartis Pharmaceuticals | Phase 2 |
| Not Yet Recruiting | Urinary G3BP as a Novel Biomarker in Lupus Nephritis NCT06520670 | Assiut University | — |
| Recruiting | Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Aut NCT06434363 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) NCT06350110 | Essen Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | T Regulatory Cells IN LUPUS NEPHRITIS NCT06428539 | Assiut University | — |
| Recruiting | Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497361 | Tongji Hospital | EARLY_Phase 1 |
| Recruiting | Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497387 | Tongji Hospital | EARLY_Phase 1 |
| Recruiting | A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic NCT06491602 | Sohag University | — |
| Recruiting | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) NCT06557265 | Nkarta, Inc. | Phase 1 / Phase 2 |
| Recruiting | The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study NCT05538208 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Unknown | Wellness & Workforce Solution for Lupus/Lupus Nephritis NCT06217107 | Morehouse School of Medicine | N/A |
| Unknown | Fibrinogen to Albumin Ratio (FAR) as a Predictive Biomarker for Lupus Nephritis (LN) NCT06288308 | Assiut University | — |
| Recruiting | The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases NCT06285279 | Nanjing University School of Medicine | Phase 1 |
| Recruiting | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Activ NCT06121297 | Cabaletta Bio | Phase 1 / Phase 2 |
| Withdrawn | A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) NCT06153095 | Lyell Immunopharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells NCT06277427 | Lingli Dong | N/A |
| Unknown | Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals. NCT06228222 | Assiut University | — |
| Recruiting | A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis NCT06406205 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis NCT06167174 | Chinese SLE Treatment And Research Group | — |
| Unknown | Assessment of Safety and Efficacy of SGLT2is Among LN Patients NCT06113900 | Ain Shams University | Phase 1 / Phase 2 |
| Terminated | A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) NCT05781750 | Kezar Life Sciences, Inc. | Phase 2 |
| Active Not Recruiting | A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 NCT06064929 | HI-Bio, A Biogen Company | Phase 1 |
| Recruiting | RY_SW01 Cell Injection Therapy in Active Lupus Nephritis NCT06058078 | Jiangsu Renocell Biotech Company | Phase 2 |
| Unknown | the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythemat NCT05964751 | Sohag University | — |
| Unknown | Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis NCT05933213 | Xiangya Hospital of Central South University | Phase 4 |
| Withdrawn | Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus NCT05101447 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Recruiting | Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythem NCT05916781 | Chinese SLE Treatment And Research Group | Phase 4 |
| Recruiting | Lupus Landmark Study: A Prospective Registry and Biorepository NCT05934149 | Lupus Research Alliance | — |
| Unknown | CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus NCT05930314 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Active Not Recruiting | KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractor NCT05938725 | Kyverna Therapeutics | Phase 1 / Phase 2 |
| Terminated | Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN) NCT05540665 | Amgen | Phase 2 |
| Recruiting | A Study of Telitacicept in Lupus Nephritis NCT05680480 | RemeGen Co., Ltd. | Phase 2 |
| Unknown | Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis NCT05863936 | Nanjing University School of Medicine | Phase 3 |
| Completed | The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis NCT05714670 | Ain Shams University | Phase 2 |
| Active Not Recruiting | An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases NCT05732402 | Alpine Immune Sciences, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic NCT05798117 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-0 NCT05810948 | argenx | Phase 2 |
| Recruiting | SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease NCT06155604 | The University of Hong Kong | Phase 2 |
| Recruiting | Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells NCT03673748 | Red de Terapia Celular | Phase 2 |
| Active Not Recruiting | KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractor NCT06342960 | Kyverna Therapeutics | Phase 1 / Phase 2 |
| Unknown | Autologous Adoptive T Regulatory Cell Transfer in Autoimmune Diseases. NCT05566977 | Ain Shams University | Phase 1 |
| Unknown | The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospecti NCT05588830 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Completed | SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis NCT05704088 | Mansoura University | Phase 4 |
| Unknown | The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment NCT05631717 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 3 |
| Completed | Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients NCT05748925 | Mansoura University | Phase 4 |
| Terminated | Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus N NCT05232864 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V NCT05268289 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study of ANX009 in Adult Participants With Lupus Nephritis NCT05780515 | Annexon, Inc. | Phase 1 |
| Unknown | MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN NCT05495893 | Second Xiangya Hospital of Central South University | Phase 4 |
| Recruiting | Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants W NCT05126277 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis NCT05432531 | Assiut University | Phase 3 |
| Recruiting | VIBRANT: VIB4920 for Active Lupus Nephritis NCT05201469 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Recruiting | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Clas NCT05039619 | Hoffmann-La Roche | Phase 2 |
| Completed | A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US NCT05337124 | Aurinia Pharmaceuticals Inc. | — |
| Recruiting | Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis NCT05207358 | Institutul Clinic Fundeni | Phase 4 |
| Active Not Recruiting | Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis NCT05138133 | AstraZeneca | Phase 3 |
| Terminated | Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) NCT05097989 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis NCT04449991 | Karolinska Institutet | N/A |
| Recruiting | Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus NCT04702256 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Unknown | Epidemiology of Lupus Nephritis in Nephrology Unit in Assiut University Hospital NCT05120882 | Assiut University | — |
| Active Not Recruiting | Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for T NCT07044115 | Beijing Mabworks Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis NCT05085418 | Zhejiang University | EARLY_Phase 1 |
| Unknown | The Expression Profile of New Complement Components in Childhood Lupus Nephritis NCT05082363 | Assiut University | — |
| Unknown | Precision Medicine in LN: A Multicenter Proof-of-concept Study for Histopathological Biomarkers Analysis in Re NCT05358652 | Fundacin Biomedica Galicia Sur | — |
| Unknown | Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis NCT04892212 | Peking Union Medical College Hospital | Phase 2 / Phase 3 |
| Unknown | A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis NCT04924296 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 |
| Unknown | Fibroblast Activating Protein Inhibitor PET Imaging in Lupus Nephritis NCT05845151 | Ruijin Hospital | N/A |
| Active Not Recruiting | Daratumumab to Treat Active Lupus Nephritis NCT04868838 | Mayo Clinic | Phase 2 |
| Completed | Comparison between2 Drugs in Lupus Nephritis NCT04424602 | Al-Azhar University | Phase 4 |
| Completed | Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis NCT04645589 | Novartis Pharmaceuticals | — |
| Terminated | Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) NCT04564339 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Withdrawn | BAFF Levels and Lupus Nephritis (LN) NCT04369495 | Universidad de Antioquia | — |
| Completed | Zanubrutinib in Participants With Active Proliferative Lupus Nephritis NCT04643470 | BeiGene | Phase 2 |
| Unknown | Epigenetics in Lupus Nephritis NCT04648059 | University of Göttingen | — |
| Terminated | A Study of Guselkumab in Participants With Active Lupus Nephritis NCT04376827 | Janssen Research & Development, LLC | Phase 2 |
| Withdrawn | Pentoxifylline in Lupus Nephritis NCT03859570 | MetroHealth Medical Center | Phase 4 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV NCT04221477 | Hoffmann-La Roche | Phase 3 |
| Unknown | Urine Exosomes to Identify Biomarkers for LN NCT04894695 | RenJi Hospital | — |
| Terminated | Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in NCT04181762 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis NCT04218890 | Assiut University | — |
| Unknown | Metformin In Prevention of Lupus Nephritis NCT04145687 | RenJi Hospital | Phase 4 |
| Completed | Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis NCT04128579 | Equillium | Phase 1 |
| Completed | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin NCT03597464 | Aurinia Pharmaceuticals Inc. | Phase 3 |
| Terminated | Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis NCT03920059 | Chulalongkorn University | Phase 4 |
| Unknown | Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis NCT03958851 | Assiut University | — |
| Unknown | Urinary T Cell Biomarker for Prediction in Lupus Nephritis NCT04320797 | Charite University, Berlin, Germany | — |
| Terminated | An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in P NCT03943147 | Bristol-Myers Squibb | Phase 2 |
| Completed | Identifying New Therapeutic Targets for Lupus Treatment NCT03921398 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Co NCT04534647 | Liga Panamericana de Asociaciones de Reumatologia (PANLAR) | — |
| Recruiting | KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis NCT03929887 | Seoul National University Hospital | — |
| Unknown | Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis NCT03214731 | Sun Yat-sen University | Phase 4 |
| Unknown | Multicenter Registry of Pediatric Lupus Nephritis in China NCT03791827 | Xiqiang Dang | — |
| Completed | Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. NCT03610516 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephriti NCT03664908 | CHU de Reims | N/A |
| Unknown | Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN) NCT03580291 | Lingyun Sun | Phase 2 |
| Completed | Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis NCT04146220 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 4 |
| Completed | A Pharmacoeconomic Study Comparing the Use of Mycophenolate Mofetil or Cyclophosphamide as Induction Therapy i NCT05195086 | Nada Magdy Mansour | — |
| Completed | Searching for Diagnostic/Prognostic Biomarkers in SLE With Renal Involvement by Proteomic Techniques NCT03687138 | Natalia A. Rivera García | — |
| Completed | Dynamic Imaging of Variation in Lupus Nephritis NCT03180021 | RILITE Foundation | — |
| Completed | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies NCT03453619 | Apellis Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis NCT03393013 | Kezar Life Sciences, Inc. | Phase 1 / Phase 2 |
| Completed | An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis NCT03385564 | Boehringer Ingelheim | Phase 2 |
| Completed | Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject with Lupus Nephritis NCT04522505 | Corestemchemon, Inc. | — |
| Unknown | Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis NCT03526042 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | N/A |
| Unknown | The Iguratimod Effect on Lupus Nephritis (IGeLU) NCT02936375 | RenJi Hospital | Phase 2 |
| Unknown | Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease NCT03201406 | National Taiwan University Hospital | — |
| Completed | Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis NCT03174587 | Corestemchemon, Inc. | Phase 1 |
| Completed | Aurinia Renal Response in Active Lupus With Voclosporin NCT03021499 | Aurinia Pharmaceuticals Inc. | Phase 3 |
| Completed | Detection of Annexin A2 in Systemic Lupus Erythematosus NCT03031925 | Centre Hospitalier Universitaire, Amiens | N/A |
| Unknown | Iguratimod as Treatment for Refractory Lupus Nephritis NCT03054545 | RenJi Hospital | N/A |
| Recruiting | The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferat NCT02954939 | The University of Hong Kong | N/A |
| Unknown | Umbilical Cord Mesenchymal Stem Cell Transplantation for Lupus Nephritis NCT03458156 | The First Affiliated Hospital of Dalian Medical University | N/A |
| Completed | Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis NCT02770170 | Boehringer Ingelheim | Phase 2 |
| Completed | Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation NCT04870359 | The University of Hong Kong | N/A |
| Completed | Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis NCT02630628 | The University of Hong Kong | Phase 3 |
| Completed | Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephri NCT02645565 | Jawaharlal Institute of Postgraduate Medical Education & Research | Phase 4 |
| Completed | A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus N NCT02550652 | Hoffmann-La Roche | Phase 2 |
| Completed | Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferativ NCT02547922 | AstraZeneca | Phase 2 |
| Completed | Rituximab and Belimumab for Lupus Nephritis NCT02260934 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis NCT02949349 | Genovate Biotechnology Co., Ltd., | Phase 2 |
| Completed | Aurinia Early Urinary Protein Reduction Predicts Response NCT02949973 | Aurinia Pharmaceuticals Inc. | Phase 2 |
| Unknown | The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mon NCT02435368 | The Third Affiliated Hospital of Southern Medical University | — |
| Completed | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment NCT02457221 | Astellas Pharma China, Inc. | Phase 3 |
| Unknown | RING - Rituximab for Lupus Nephritis With Remission as a Goal NCT01673295 | Frédéric A. Houssiau, MD, PhD | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis NCT02256150 | Asahi Kasei Therapeutics Corporation | Phase 3 |
| Terminated | ACTHar in the Treatment of Lupus Nephritis NCT02226341 | Columbia University | Phase 4 |
| Recruiting | Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus NCT05443516 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | — |
| Terminated | Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN) NCT02176486 | Takeda | Phase 1 |
| Completed | AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) NCT02141672 | Aurinia Pharmaceuticals Inc. | Phase 2 |
| Completed | Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis NCT04318600 | Yan'an Affiliated Hospital of Kunming Medical University | Phase 1 |
| Unknown | Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla) NCT02313974 | Hospital de Clinicas José de San Martín | — |
| Terminated | BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis NCT01930890 | Biogen | Phase 2 |
| Recruiting | High Quality Evidence of Chinese Lupus Nephritis (HELP) NCT03001973 | Sun Yat-sen University | — |
| Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurolo NCT01931644 | Sanguine Biosciences | — |
| Completed | Functional MRI in Lupus Nephritis NCT01731054 | Biogen | — |
| Completed | The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients NCT02493101 | Chulalongkorn University | — |
| Recruiting | Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID) NCT01802034 | The Rogosin Institute | — |
| Terminated | Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis NCT01714817 | Bristol-Myers Squibb | Phase 3 |
| Terminated | Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy NCT01765842 | Fundación Pública Andaluza Progreso y Salud | Phase 3 |
| Completed | Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis NCT02453997 | The University of Hong Kong | — |
| Completed | Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis NCT01639339 | Human Genome Sciences Inc., a GSK Company | Phase 3 |
| Terminated | BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis NCT01499355 | Biogen | Phase 2 |
| Completed | Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephri NCT01580865 | Ramathibodi Hospital | N/A |
| Completed | Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients NCT04266860 | Qure Healthcare, LLC | N/A |
| Unknown | Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis NCT01539902 | CytoMed & Beike | Phase 2 |
| Completed | Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients NCT01470183 | Columbia University | — |
| Completed | An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis NCT01273389 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis NCT03828071 | Nanjing University School of Medicine | N/A |
| Terminated | Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil NCT01369628 | EMD Serono | Phase 1 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients NCT01316133 | Astellas Pharma Korea, Inc. | Phase 4 |
| Terminated | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis NCT01342016 | Astellas Pharma Inc | Phase 3 |
| Withdrawn | Clinical Trial Treatment in Lupus Nephritis NCT01299922 | Hospital Universitario Fundación Alcorcón | Phase 3 |
| Withdrawn | Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis NCT01288664 | Sun Yat-sen University | Phase 3 |
| Unknown | Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis NCT01226147 | Kinki University | Phase 2 |
| Completed | A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis NCT01085097 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Completed | Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis NCT01206569 | Chinese University of Hong Kong | Phase 4 |
| Withdrawn | Velcade for Proliferative Lupus Nephritis NCT01169857 | The Rogosin Institute | Phase 4 |
| Completed | Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis NCT01203709 | Tuen Mun Hospital | Phase 4 |
| Completed | Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis NCT01056237 | Zhi-Hong Liu, M.D. | N/A |
| Terminated | The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resista NCT01015456 | Chulalongkorn University | Phase 3 |
| Completed | Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis NCT01042457 | Chulalongkorn University | Phase 3 |
| Completed | Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria NCT00935389 | Nanjing University School of Medicine | N/A |
| Completed | Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis NCT00876616 | Zhi-Hong Liu, M.D. | N/A |
| Completed | To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephri NCT00881309 | Nanjing University School of Medicine | N/A |
| Withdrawn | Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis NCT00908986 | Northwell Health | N/A |
| Completed | Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis NCT00774852 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg NCT00705367 | Bristol-Myers Squibb | Phase 1 |
| Unknown | Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis NCT00659217 | Organ Transplant Institute, China | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) NCT00626197 | Genentech, Inc. | Phase 3 |
| Terminated | Etanercept for the Treatment of Lupus Nephritis NCT00447265 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis NCT00573157 | EMD Serono | Phase 2 / Phase 3 |
| Unknown | A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis NCT00569101 | Seoul National University Hospital | Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations NCT01410747 | Astellas Pharma Inc | — |
| Terminated | A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis. NCT00425438 | Hoffmann-La Roche | Phase 3 |
| Completed | Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for NCT00423098 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Phase Ib Study of SC Milatuzumab in SLE NCT01845740 | Gilead Sciences | Phase 1 |
| Terminated | TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) NCT00368264 | Medical University of Vienna | Phase 2 / Phase 3 |
| Completed | Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Inducti NCT00615173 | Sun Yat-sen University | Phase 3 |
| Terminated | A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis NCT02081183 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/ NCT00282347 | Genentech, Inc. | Phase 3 |
| Completed | A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis NCT00404794 | Hospital Authority, Hong Kong | Phase 3 |
| Completed | Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephrit NCT00371319 | Tuen Mun Hospital | Phase 4 |
| Completed | Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis NCT00298506 | Nanjing University School of Medicine | N/A |
| Completed | A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis. NCT00377637 | Hoffmann-La Roche | Phase 3 |
| Terminated | Study of LJP 394 in Lupus Patients With History of Renal Disease NCT00089804 | La Jolla Pharmaceutical Company | Phase 3 |
| Completed | Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) NCT00094380 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN NCT00302549 | Nanjing University School of Medicine | N/A |
| Completed | Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis NCT00125307 | Chinese University of Hong Kong | Phase 4 |
| Completed | Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis NCT00709722 | Nippon Kayaku Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Compa NCT00429377 | Astellas Pharma Inc | Phase 3 |
| Completed | Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis NCT01207297 | Zhejiang University | Phase 1 |
| Completed | Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study NCT00976300 | Institute of Rheumatology, Prague | Phase 2 |
| Completed | Lupus Nephritis: Role of Environmental and Occupational Exposures NCT00342329 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis. NCT00204022 | Frédéric A. Houssiau, MD, PhD | Phase 3 |
| Completed | BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis NCT00001789 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Completed | Cyclophosphamide and Fludarabine to Treat Lupus Nephritis NCT00001676 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 1 |
| Completed | Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease NCT00035308 | La Jolla Pharmaceutical Company | Phase 3 |
| Withdrawn | Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis NCT00539799 | Cambridge University Hospitals NHS Foundation Trust | Phase 3 |
| Withdrawn | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled i NCT00404157 | Genentech, Inc. | Phase 3 |